MDxHealth and Exact Sciences collaborate for epigenetics and molecular diagnostics

27 April 2017 (Last Updated April 27th, 2017 18:30)

MDxHealth has entered a new five-year agreement with diagnostics company Exact Sciences to share technologies that will be discovered and developed in the epigenetics and molecular diagnostic fields.

MDxHealth has entered a new five-year agreement with diagnostics company Exact Sciences to share technologies that will be discovered and developed in the epigenetics and molecular diagnostic fields.

The collaboration also provides opportunities to study technology in relation to urologic and lung cancers.

MDxHealth chief scientific officer Dr Wim van Criekinge said: "Exact Sciences is an ideal partner for us to collaborate with in the identification and development of new biomarkers for clinical diagnostic products.

"The partnership may allow each party to better capitalise on its cutting-edge epigenetic research and development efforts to improve patients lives by bringing new products and services to the market."

At the same time, Exact Sciences is purchasing biomarker and technology patents from MdxHealth.

"The partnership may allow each party to better capitalise on its cutting-edge epigenetic research and development efforts to improve patients lives by bringing new products and services to the market."

The patents cover the DNA methylation biomarker for colorectal cancer called NDRG4 and also the technology employed for the faecal immunochemical test (FIT), which is used in combination with methylation.

The acquisitions involve a total payment of $15m, including payments accrued since July last year.

Exact Sciences chief scientific officer and R&D senior vice-president Dr Graham Lidgard said: "We will continue our long-standing scientific co-operation through this new agreement, which has the potential to benefit both companies' product development programmes."